PL168609B1 - Sposób wytwarzania nowych cyklosporyn PL PL - Google Patents
Sposób wytwarzania nowych cyklosporyn PL PLInfo
- Publication number
- PL168609B1 PL168609B1 PL91292248A PL29224891A PL168609B1 PL 168609 B1 PL168609 B1 PL 168609B1 PL 91292248 A PL91292248 A PL 91292248A PL 29224891 A PL29224891 A PL 29224891A PL 168609 B1 PL168609 B1 PL 168609B1
- Authority
- PL
- Poland
- Prior art keywords
- ciclosporin
- cells
- cyclosporins
- cyclosporin
- hiv
- Prior art date
Links
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 34
- 108010036941 Cyclosporins Proteins 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 11
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 56
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 241001149960 Tolypocladium inflatum Species 0.000 claims abstract description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 46
- 229930105110 Cyclosporin A Natural products 0.000 claims description 14
- 241000233866 Fungi Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 abstract description 5
- 230000002538 fungal effect Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 230000001506 immunosuppresive effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 102000001493 Cyclophilins Human genes 0.000 description 13
- 108010068682 Cyclophilins Proteins 0.000 description 13
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000036436 anti-hiv Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- -1 e.g. Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GBIWPCXWDSDANU-JYFGSSRXSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,18,19,25,28-decamethyl-6,9,24-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,2 Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GBIWPCXWDSDANU-JYFGSSRXSA-N 0.000 description 1
- GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- 208000037859 AIDS-related disorder Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010019251 cyclosporin H Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 108010040781 dihydrocyclosporin D Proteins 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909023859A GB9023859D0 (en) | 1990-11-02 | 1990-11-02 | Chemical products |
| GB909023972A GB9023972D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB909023970A GB9023970D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB909023971A GB9023971D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB919116836A GB9116836D0 (en) | 1991-08-05 | 1991-08-05 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL292248A1 PL292248A1 (en) | 1992-07-27 |
| PL168609B1 true PL168609B1 (pl) | 1996-03-29 |
Family
ID=27517009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL91292248A PL168609B1 (pl) | 1990-11-02 | 1991-10-31 | Sposób wytwarzania nowych cyklosporyn PL PL |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US5767069A (enExample) |
| EP (1) | EP0484281B2 (enExample) |
| JP (1) | JP2740775B2 (enExample) |
| KR (1) | KR100203556B1 (enExample) |
| AT (1) | ATE148469T1 (enExample) |
| AU (1) | AU649277B2 (enExample) |
| CA (1) | CA2054590C (enExample) |
| CY (1) | CY2159B1 (enExample) |
| CZ (1) | CZ280909B6 (enExample) |
| DE (1) | DE69124459T3 (enExample) |
| DK (1) | DK0484281T4 (enExample) |
| ES (1) | ES2095926T5 (enExample) |
| FI (1) | FI111730B (enExample) |
| GR (2) | GR3022592T3 (enExample) |
| HK (1) | HK1005741A1 (enExample) |
| HU (1) | HU212674B (enExample) |
| IE (1) | IE913824A1 (enExample) |
| IL (1) | IL99912A (enExample) |
| MX (1) | MX9101869A (enExample) |
| MY (1) | MY134806A (enExample) |
| NZ (1) | NZ240421A (enExample) |
| PL (1) | PL168609B1 (enExample) |
| PT (1) | PT99410B (enExample) |
| SA (1) | SA92120344B1 (enExample) |
| SK (1) | SK278808B6 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0624093A1 (en) * | 1992-01-28 | 1994-11-17 | KARPAS, Abraham | The use of a compound for the manufacture of a medicament for the treatment of hiv infection |
| GB9204466D0 (en) * | 1992-03-02 | 1992-04-15 | Sandoz Ltd | Improvements in or relating to organic compounds |
| ES2065273B1 (es) * | 1993-05-25 | 1995-09-16 | Biogal Gyogyszergyar | Procedimiento para la purificacion de ciclosporina a. |
| US5639852A (en) * | 1994-09-01 | 1997-06-17 | Wisconsin Alumni Research Foundation | Immunostimulatory agents |
| US5948693A (en) * | 1994-09-01 | 1999-09-07 | Wisconsin Alumni Research Foundation | Solid phase synthesis of immunosuppressive agents |
| US6696413B2 (en) | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| DE59608274D1 (de) * | 1995-07-17 | 2002-01-03 | Chem Ag Binningen C | Cyclosporin-derivate mit anti-hiv-wirkung |
| JP3089350B2 (ja) * | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | シクロフィリンロタマーゼ活性の阻害剤 |
| CA2248192A1 (en) * | 1996-03-12 | 1997-09-18 | Picower Institute For Medical Research | Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity |
| CN1130373C (zh) * | 1996-09-13 | 2003-12-10 | 诺瓦蒂斯有限公司 | [3'－脱氧－3'－氧代－MeBmt]'环孢菌素制备方法 |
| FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| CA2298572C (en) | 1997-10-08 | 2002-04-09 | Isotechnika Inc. | Deuterated cyclosporine analogs and their use as immunomodulating agents |
| ZA99981B (en) * | 1998-02-17 | 2000-08-08 | Du Pont Pharm Co | Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors. |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| FR2780061B1 (fr) | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| EP1091975B1 (fr) | 1998-07-01 | 2005-12-14 | Debiopharm S.A. | Nouvelle cyclosporine ayant un profil d'activite ameliore |
| DK1154759T3 (da) | 1998-12-30 | 2008-12-08 | Dexcel Ltd | Dispergerbart koncentrat til indgift af cyclosporin |
| US6521595B1 (en) * | 1999-11-19 | 2003-02-18 | Lg Chemical, Ltd. | Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| CN1507451A (zh) * | 2001-04-20 | 2004-06-23 | �±Ȱ·�ķ�ɷ�����˾ | 可用作前体药物的修饰环孢菌素及其应用 |
| KR100695611B1 (ko) * | 2001-05-17 | 2007-03-14 | 주식회사 엘지생활건강 | [감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제 |
| PT1436321E (pt) | 2001-10-19 | 2006-10-31 | Isotechnika Inc | Sintese de analogos de ciclosporina |
| DE60233150D1 (de) * | 2001-10-19 | 2009-09-10 | Isotechnika Inc | Neue cyclosporin-analoge mikroemulsionsvorkonzentrate |
| AU2002347102A1 (en) * | 2001-10-25 | 2003-05-12 | Hans Will | Means for inhibition of the synthesis of viral proteins |
| US7108988B2 (en) * | 2001-11-02 | 2006-09-19 | The J. David Gladstone Institutes | Methods of identifying agents for inhibiting lentivirus replication |
| EP1603512A2 (en) | 2003-03-17 | 2005-12-14 | Albany Molecular Research, Inc. | Novel cyclosporins |
| GB0320638D0 (en) * | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US20050059583A1 (en) * | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| CN1964735A (zh) * | 2004-04-08 | 2007-05-16 | 诺瓦提斯公司 | 环孢菌素用于治疗脑局部缺血以及脑和脊髓损伤的用途 |
| CA2573400A1 (en) * | 2004-07-13 | 2006-01-19 | Novartis Ag | Cyclosporins to treat alzheimer's disease |
| RU2394589C2 (ru) | 2004-07-14 | 2010-07-20 | Новартис Аг | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) |
| KR100597309B1 (ko) | 2004-09-17 | 2006-07-05 | 주식회사 핸슨바이오텍 | 세베키아 베니하나를 이용한 [감마 히드록실메틸루신4] 사이클로스포린 a의 제조방법 |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US7378391B2 (en) * | 2004-09-29 | 2008-05-27 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| RU2399628C2 (ru) * | 2004-10-01 | 2010-09-20 | Скайнексис, Инк. | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| JP2008515886A (ja) | 2004-10-06 | 2008-05-15 | エーエムアール テクノロジー インコーポレイテッド | シクロスポリンアルキンおよびそれらの医用薬剤としての有用性 |
| US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
| US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
| KR100777488B1 (ko) | 2004-12-15 | 2007-11-28 | 주식회사 핸슨바이오텍 | 세베키아 베니하나 (Sebekia benihana)배양물로부터 감마-히드록실메틸루신4 사이클로스포린 A를 효과적이고 선택적으로 회수하는 방법 |
| CA2587586A1 (en) * | 2004-12-23 | 2006-07-06 | Novartis Ag | Compounds for flaviviridae treatment |
| BRPI0519345A2 (pt) | 2004-12-23 | 2009-01-20 | Novartis Ag | composiÇço para tratamento do hcv |
| WO2007041631A1 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| KR101059593B1 (ko) | 2006-04-11 | 2011-08-25 | 노파르티스 아게 | Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도 |
| JP5377293B2 (ja) | 2006-05-19 | 2013-12-25 | スシネキス インク | 眼疾患の治療及び予防方法 |
| KR101089112B1 (ko) * | 2006-06-02 | 2011-12-06 | 피씨 제스띠옹 에스.아.에스. | 활성 전자 관리 |
| WO2008069917A2 (en) * | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| WO2009042892A1 (en) * | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| US9090671B2 (en) * | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| US20130190223A1 (en) * | 2008-07-30 | 2013-07-25 | Isotechnika Pharma Inc. | Nonimmunosuppressive cyclosporine analogue molecules |
| US8536114B2 (en) | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| GB0909754D0 (en) * | 2009-06-05 | 2009-07-22 | Magnani Mauro | Drug delivery systems |
| CA2784600A1 (en) * | 2009-12-21 | 2011-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New inhibitors of cyclophilins and uses thereof |
| JP2013516424A (ja) | 2009-12-30 | 2013-05-13 | サイネクシス，インコーポレーテッド | シクロスポリン類似体 |
| WO2012009715A2 (en) | 2010-07-16 | 2012-01-19 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| US9011833B2 (en) | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| AU2011342284C1 (en) | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| US20120253007A1 (en) * | 2011-03-28 | 2012-10-04 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Synthesis of Cyclosporin H |
| US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016205423A2 (en) | 2015-06-15 | 2016-12-22 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| JP2021531348A (ja) | 2018-07-20 | 2021-11-18 | リポシン，インク． | 肝臓病 |
| CN111449050A (zh) | 2019-01-20 | 2020-07-28 | 睿诺医疗科技（上海）有限公司 | 环孢菌素类似物及其用途 |
| WO2021068957A1 (en) | 2019-10-12 | 2021-04-15 | Farsight Medical Technology (Shanghai) Co., Ltd. | Treatment and prevention of nephrotoxin-induced kidney injuries |
| BR112022018929A2 (pt) | 2020-03-26 | 2022-12-06 | Farsight Medical Tech Shanghai Co Ltd | Inibidores da ciclofilina e seus usos |
| EP4135743A4 (en) | 2020-04-15 | 2024-05-22 | Farsight Medical Technology (Shanghai) Co., Ltd. | Prevention and treatment of organ injuries |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2455859C2 (de) | 1973-12-06 | 1983-12-15 | Sandoz-Patent-GmbH, 7850 Lörrach | Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung |
| US4304855A (en) * | 1977-05-05 | 1981-12-08 | The Upjohn Company | Allylic methyl-hydroxylated novobiocins |
| CH667274A5 (de) * | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4814323A (en) * | 1986-03-25 | 1989-03-21 | Andrieu J M | Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus |
| EP0283801A3 (en) * | 1987-03-27 | 1990-05-30 | Abbott Laboratories | Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies |
| US4798823A (en) * | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
| DE3888357T2 (de) * | 1987-06-22 | 1994-09-15 | Merck & Co Inc | Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen. |
| GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
| US4981799A (en) * | 1987-08-21 | 1991-01-01 | Takeda Chemical Industries, Ltd. | Acylamino acid racemase, production and use thereof |
| US4914188A (en) † | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
| US5081024A (en) * | 1988-09-05 | 1992-01-14 | Nissan Chemical Industries, Ltd. | Process for producing optically active amino acids |
| US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
-
1991
- 1991-10-30 DE DE69124459T patent/DE69124459T3/de not_active Expired - Lifetime
- 1991-10-30 SK SK3297-91A patent/SK278808B6/sk not_active IP Right Cessation
- 1991-10-30 DK DK91810841T patent/DK0484281T4/da active
- 1991-10-30 ES ES91810841T patent/ES2095926T5/es not_active Expired - Lifetime
- 1991-10-30 FI FI915135A patent/FI111730B/fi not_active IP Right Cessation
- 1991-10-30 AT AT91810841T patent/ATE148469T1/de not_active IP Right Cessation
- 1991-10-30 EP EP91810841A patent/EP0484281B2/en not_active Expired - Lifetime
- 1991-10-30 CZ CS913297A patent/CZ280909B6/cs not_active IP Right Cessation
- 1991-10-31 CA CA002054590A patent/CA2054590C/en not_active Expired - Lifetime
- 1991-10-31 NZ NZ240421A patent/NZ240421A/en not_active IP Right Cessation
- 1991-10-31 AU AU86923/91A patent/AU649277B2/en not_active Expired
- 1991-10-31 MX MX9101869A patent/MX9101869A/es unknown
- 1991-10-31 IL IL9991291A patent/IL99912A/en not_active IP Right Cessation
- 1991-10-31 PT PT99410A patent/PT99410B/pt not_active IP Right Cessation
- 1991-10-31 PL PL91292248A patent/PL168609B1/pl unknown
- 1991-11-01 IE IE382491A patent/IE913824A1/en not_active IP Right Cessation
- 1991-11-01 KR KR1019910019402A patent/KR100203556B1/ko not_active Expired - Lifetime
- 1991-11-01 JP JP3287501A patent/JP2740775B2/ja not_active Expired - Lifetime
- 1991-11-01 MY MYPI91002021A patent/MY134806A/en unknown
- 1991-11-01 HU HU913446A patent/HU212674B/hu unknown
-
1992
- 1992-01-19 SA SA92120344A patent/SA92120344B1/ar unknown
-
1995
- 1995-04-24 US US08/427,312 patent/US5767069A/en not_active Expired - Lifetime
-
1997
- 1997-02-19 GR GR970400277T patent/GR3022592T3/el unknown
-
1998
- 1998-05-26 US US09/084,709 patent/US5981479A/en not_active Expired - Lifetime
- 1998-06-03 HK HK98104804A patent/HK1005741A1/en not_active IP Right Cessation
-
1999
- 1999-09-09 US US09/392,282 patent/US6255100B1/en not_active Expired - Fee Related
-
2000
- 2000-01-13 CY CY0000002A patent/CY2159B1/xx unknown
-
2001
- 2001-01-31 GR GR20010400150T patent/GR3035323T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL168609B1 (pl) | Sposób wytwarzania nowych cyklosporyn PL PL | |
| HK1005741B (en) | Cyclosporins | |
| DE69928938T2 (de) | Neues cyclosporin mit verbesserter wirkung | |
| Iwamoto et al. | WF11899A, B and C, novel antifungal lipopeptides I. Taxonomy, fermentation, isolation and physico-chemical properties | |
| US4914188A (en) | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin | |
| CS249542B2 (en) | Method of cyclosporines production | |
| Sakamoto et al. | FR901459, A NOVEL IMMUNOSUPPRESSANT ISOLATED FROM Stachybotrys chartarum No. 19392 TAXONOMY OF THE PRODUCING ORGANISM, FERMENTATION, ISOLATION, PHYSICO-CHEMICAL PROPERTIES AND BIOLOGICAL ACTIVITIES | |
| GB2207678A (en) | Novel immunosuppressive fluorinated cyclosporin analogs | |
| RU2085589C1 (ru) | Циклоспорины | |
| RO110144B1 (ro) | Noi ciclosporine, procedeu de sinteză a acestora și metodă de tratament și prevenire a SIDA | |
| RU2272643C2 (ru) | Высокоактивный кристаллический препарат циклоспорина а и способ его получения | |
| NO310028B1 (no) | Cyklosporiner, deres anvendelse og fremstilling samt en biologisk ren kilde | |
| EP0553133A1 (en) | Analogues of cyclolinopeptide a and the use thereof |